scholarly journals The blood pressure control and arteriosclerotic cardiovascular risk among Chinese community hypertensive patients

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Shijun Liu ◽  
Hanyan Yuan ◽  
Caixia Jiang ◽  
Jue Xu ◽  
Xin Qiu ◽  
...  

AbstractThe present study aimed to describe the blood pressure (BP) control rate and 10-years arteriosclerotic cardiovascular disease (ASCVD) risk estimation among community hypertensive patients. A total of 196,803 subjects were enrolled. The control rates calculated as the intensive (SBP < 130 mmHg and DBP < 80 mmHg) and standard (SBP < 140 mmHg and DBP < 90 mmHg) threshold. Multivariable logistic analysis was employed to assess the associations between cardiovascular factors and BP control. Sensitivity, specificity and Youden’s index were used to identify the ability of high risk of ASCVD estimation by different thresholds. The control rate was 16.34% and 50.25% by the intensive and standard threshold, respectively. Besides regular medication, the risk factors for BP control included older age, male, unhealthy lifestyle, obesity, dyslipidemia and abnormal FPG. 25.08% of subjects had high risk of 10-years ASCVD estimation. The sensitivity, specificity and Youden’s index of intensive threshold was 84.37%, 16.15% and 0.51%, and were significantly different from 50.55%, 50.42% and 0.98% of the standard threshold, respectively. Half of community hypertensive patients did not control BP, and nearly a quarter have high risk of 10-years ASCVD risk estimation. The intensive threshold resulted in a one-third reduction in the control rate compared to the standard threshold. No matter which threshold was used, a single BP control status seemed not a suitable indicator for identification of high risk of 10-years ASCVD risk estimation.

2010 ◽  
Vol 28 ◽  
pp. e108
Author(s):  
MA Prieto Diaz ◽  
JA Divison Garrote ◽  
J Abellan Aleman ◽  
JL Llisterri Caro ◽  
NR Robles P&;eacute;rez-Monteoliva ◽  
...  

2021 ◽  
Vol 78 (19) ◽  
pp. B3
Author(s):  
Victor Zeijen ◽  
Melvin Lafeber ◽  
Jorie Versmissen ◽  
Abraham Kroon ◽  
Eric Boersma ◽  
...  

PLoS ONE ◽  
2011 ◽  
Vol 6 (9) ◽  
pp. e24569 ◽  
Author(s):  
José R. Banegas ◽  
Krista Lundelin ◽  
Mariano de la Figuera ◽  
Juan J. de la Cruz ◽  
Auxiliadora Graciani ◽  
...  

2012 ◽  
Vol 8 (3) ◽  
pp. 192
Author(s):  
Patricia Fonseca ◽  
Anna F Dominiczak ◽  
Stephen Harrap ◽  
◽  
◽  
...  

Early combination therapy is more effective for hypertension control in high-risk patients than monotherapy, and current guidelines recommend the use of either an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) for first-line therapy in patients younger than 55 years. Recent evidence shows that ACEIs reduce mortality, whereas ARBs show no apparent benefit despite their blood pressure lowering action. However, it is important to consider which blood pressure parameters should be targeted given that different drugs have distinct effects on key parameters. Remarkably, a high percentage of hypertensive patients whose treatment has brought these parameters within target ranges still remain at high risk of cardiovascular disease due to additional risk factors. Combination therapy with synergistic effects on blood pressure and metabolic control should thus be considered for the long-term treatment of hypertensive patients with co-morbid conditions.


Sign in / Sign up

Export Citation Format

Share Document